Shinya Omoto

2.5k total citations · 1 hit paper
33 papers, 1.9k citations indexed

About

Shinya Omoto is a scholar working on Molecular Biology, Epidemiology and Immunology. According to data from OpenAlex, Shinya Omoto has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Epidemiology and 10 papers in Immunology. Recurrent topics in Shinya Omoto's work include Influenza Virus Research Studies (9 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Respiratory viral infections research (6 papers). Shinya Omoto is often cited by papers focused on Influenza Virus Research Studies (9 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Respiratory viral infections research (6 papers). Shinya Omoto collaborates with scholars based in Japan, United States and Australia. Shinya Omoto's co-authors include Yoichi Robertus Fujii, Edward S. Mocarski, Takao Shishido, Takeki Uehara, Takashi Hashimoto, Hongyan Guo, William J. Kaiser, Akira Naito, Takeshi Noshi and Makoto Kawai and has published in prestigious journals such as Journal of Biological Chemistry, Clinical Infectious Diseases and Journal of Power Sources.

In The Last Decade

Shinya Omoto

33 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil

2018 312 citations Shinya Omoto, Valentina Speranzini et al. Scientific Reports profile →

Peers

Countries citing papers authored by Shinya Omoto

Since Specialization

Citations

This map shows the geographic impact of Shinya Omoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinya Omoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinya Omoto more than expected).

Fields of papers citing papers by Shinya Omoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinya Omoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinya Omoto. The network helps show where Shinya Omoto may publish in the future.

Co-authorship network of co-authors of Shinya Omoto

This figure shows the co-authorship network connecting the top 25 collaborators of Shinya Omoto. A scholar is included among the top collaborators of Shinya Omoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinya Omoto. Shinya Omoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults 2024 ·Scientific Reports ·Satoshi Iwata, Andrew J. Pollard, Yukio Tada, Shinya Omoto, (unknown), (unknown), (unknown), Mari Ariyasu, Takuhiro Sonoyama	2
2	The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir 2024 ·Archives of Virology ·K. Taniguchi, Takeshi Noshi, Shinya Omoto, Akihiko Sato, Takao Shishido, Keita Matsuno, Masatoshi Okamatsu, Scott Krauss, Richard J. Webby, Yoshihiro Sakoda, Hiroshi Kida	4
3	Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan 2023 ·Vaccine X ·Takuhiro Sonoyama, (unknown), (unknown), (unknown), Shinya Omoto, (unknown), Mari Ariyasu	1
4	A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses via α-tocopherol component 2023 ·Frontiers in Immunology ·Y. Yoshioka, Kouji Kobiyama, Tomoya Hayashi, Motoyasu Onishi, (unknown), Takayuki Nakagawa, (unknown), Anri Nishinaka, Jun Hirose, (unknown), (unknown), Atsushi Hayata, Satoru Ishida, Shinya Omoto, Morio Nagira, Ken J. Ishii	6
5	Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model 2022 ·Communications Biology ·(unknown), Edin Mifsud, Steffen Wildum, (unknown), (unknown), Takao Shishido, Satoshi Kojima, Shinya Omoto, Keiko Baba, (unknown), Aeron C. Hurt, Ian Barr	7
6	Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study 2022 ·Vaccine ·Masaharu Shinkai, Takuhiro Sonoyama, (unknown), (unknown), (unknown), Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, (unknown), Mari Ariyasu	12
7	Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys 2022 ·Vaccine ·(unknown), Noriyo Nagata, Tomoyuki Homma, Hiroki Maeda, Keiji Dohi, (unknown), (unknown), Naoko Iwata‐Yoshikawa, (unknown), Yusuke Sakai, Masayuki Shirakura, Noriko Kishida, (unknown), Yasushi Suzuki, Shinji Watanabe, Hideki Asanuma, Takuhiro Sonoyama, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa	11
8	Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings 2022 ·Vaccine ·Satoshi Iwata, Takuhiro Sonoyama, (unknown), (unknown), Tomoyuki Homma, Shinya Omoto, (unknown), Mari Ariyasu	11
9	Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults 2022 ·Vaccine ·Takuhiro Sonoyama, Satoshi Iwata, Masaharu Shinkai, Naoko Iwata‐Yoshikawa, (unknown), (unknown), Akira Ainai, Noriyo Nagata, Nobuaki Matsunaga, Yukio Tada, Tomoyuki Homma, Shinya Omoto, (unknown), (unknown), Tadaki Suzuki, Hideki Hasegawa, Mari Ariyasu	2
10	Electrochemical impedance analysis on positive electrode in lithium-ion battery with galvanostatic control 2021 ·Journal of Power Sources ·Hikari Watanabe, Shinya Omoto, Yoshinao Hoshi, Isao Shitanda, Masayuki Itagaki	53
11	Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model 2021 ·PLoS Pathogens ·Leo Lee, Jie Zhou, (unknown), Rebecca Frise, (unknown), Keiko Baba, Shahjahan Miah, Takao Shishido, Mónica Galiano, Takashi Hashimoto, Shinya Omoto, Takeki Uehara, Edin Mifsud, Neil Collinson, (unknown), Barry Clinch, Steffen Wildum, William Barclay, Aeron C. Hurt	29
12	Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil 2020 ·Influenza and Other Respiratory Viruses ·Takashi Hashimoto, Keiko Baba, (unknown), (unknown), Satoshi Hata, Takao Shishido, Akira Naito, Steffen Wildum, Shinya Omoto	24
13	Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil breakdown → 2018 ·Scientific Reports ·Shinya Omoto, Valentina Speranzini, Takashi Hashimoto, Takeshi Noshi, Hiroto Yamaguchi, Makoto Kawai, Keiko Kawaguchi, Takeki Uehara, Takao Shishido, Akira Naito, S. Cusack	312
14	In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit 2018 ·Antiviral Research ·Takeshi Noshi, Mitsutaka Kitano, K. Taniguchi, Atsuko Yamamoto, Shinya Omoto, Keiko Baba, Takashi Hashimoto, (unknown), (unknown), Kazunari Hattori, Makoto Kawai, Ryu Yoshida, Masanori Kobayashi, Tomokazu Yoshinaga, Akihiko Sato, Masatoshi Okamatsu, Yoshihiro Sakoda, Hiroshi Kida, Takao Shishido, Akira Naito	267
15	Herpes Simplex Virus Suppresses Necroptosis in Human Cells 2015 ·Cell Host & Microbe ·Hongyan Guo, Shinya Omoto, Philip A. Harris, Joshua N. Finger, John Bertin, Peter J. Gough, William J. Kaiser, Edward S. Mocarski	207
16	Suppression of RIP3-dependent Necroptosis by Human Cytomegalovirus 2015 ·Journal of Biological Chemistry ·Shinya Omoto, Hongyan Guo, Ganesh R. Talekar, Linda Roback, William J. Kaiser, Edward S. Mocarski	117
17	Transcription of True Late (γ2) Cytomegalovirus Genes Requires UL92 Function That Is Conserved among Beta- and Gammaherpesviruses 2013 ·Journal of Virology ·Shinya Omoto, Edward S. Mocarski	33
18	A Strategy for Neuraminidase Inhibitors Using Mechanism‐Based Labeling Information 2011 ·Chemistry - An Asian Journal ·Hiroshi Hinou, (unknown), (unknown), (unknown), Masaki Kurogochi, (unknown), Xiao‐Dong Gao, Nobuaki Miura, Naoki Fujitani, Shinya Omoto, Tomokazu Yoshinaga, Tamio Fujiwara, Takeshi Noshi, Hiroko Togame, Hiroshi Takemoto, Shin‐Ichiro Nishimura	7
19	Cloning and Detection of HIV-1-Encoded MicroRNA 2006 ·Humana Press eBooks ·Shinya Omoto, Yoichi Robertus Fujii	12
20	A Potential Live Vector, Foamy Virus, Directed Intra-Cellular Expression of Ovine Interferon-.TAU. Exhibited the Resistance to HIV Infection 2004 ·Journal of Veterinary Medical Science ·Yoichi Robertus Fujii, (unknown), Kaori Otake, (unknown), Shinya Omoto, Hidetoshi Hayashi, (unknown), Noriko Okada, (unknown), Harumi Okuyama, Kazuhiko Imakawa	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact